GEO-CM04S1 vs mRNA SARS-COV-2 Vaccine

A Phase 2 Randomized, Multi-center Study of GEO-CMO4S1 (SARS-CoV-2 Vaccine) Versus mRNA SARS-CoV-2 Vaccine in Patients Post Cellular Therapy for Hematological Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
240 patients (estimated)
Sponsors
GeoVax, Inc.
Tags
Vaccine, COVID-19 Trials, Randomization
Trial Type
Supportive
Last Update
10 months ago
SparkCures ID
1889
NCT Identifier
NCT04977024

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.